Corporate Profile
Enabling protein-protein interactions and rapid ELISA in minutes
T
he Octet RED96 system can rapid- ly measure protein and other bio- molecule concentrations, as well as determine kinetics, affinity and specificity of protein-protein and protein-small mole- cule interactions. It extends the capabilities of the company’s premier Octet RED plat- form by featuring biosensor re-racking, which enables more efficient workflow, reduced amounts of capture molecule use and lower assay-running costs. The new Octet RED96 system enables life science researchers to perform analyses that have traditionally been conducted with SPR, HPLC, ELISA and other single-purpose microfluidics instruments with unmatched performance and cost-efficiency. ForteBio’s Octet platform is based on the company’s proprietary BioLayer Interferometry (BLI) technology, which uses optical biosensors to measure multiple interactions in parallel, without the use of detec- tion agents. The Octet platform consists of 8- and 16-channel instruments that accommodate 96- and 384-well assay formats. All Octet biosensors are designed to simplify kinetic characterisation and quantitation by elimi- nating throughput and time-
Drug Discovery World Summer 2011 About Fortebio, Inc
to-result limitations of traditional SPR- based assays and ELISA. The Octet biosen- sors are disposable, configured in a stan- dard microplate format and are coated with a proprietary biocompatible matrix that is uniform, non-denaturing and has minimal non-specific binding.
ForteBio is a life science company that pro- vides analytical systems to accelerate bio- therapeutic drug discovery and develop- ment. These systems enable real-time, label-free analysis of biomolecular interac- tions, providing information on affinity, kinetics and concentration. ForteBio’s ana- lytical capabilities enable significantly easi- er, faster and better characterisation of drug candidates, thus providing greater value in drug development applications where existing methods have limitations in throughput, performance and cost. ForteBio recently announced the shipment of greater than three million Dip and Read™ biosensors, signalling a rapid adop- tion of the companies’ label-free technology in academic research and drug discovery. The com- pany is headquartered in Menlo Park, California, with wholly-owned subsidiaries in London and Shanghai. For more information, visit
www.fortebio.com.
79
Page 1 |
Page 2 |
Page 3 |
Page 4 |
Page 5 |
Page 6 |
Page 7 |
Page 8 |
Page 9 |
Page 10 |
Page 11 |
Page 12 |
Page 13 |
Page 14 |
Page 15 |
Page 16 |
Page 17 |
Page 18 |
Page 19 |
Page 20 |
Page 21 |
Page 22 |
Page 23 |
Page 24 |
Page 25 |
Page 26 |
Page 27 |
Page 28 |
Page 29 |
Page 30 |
Page 31 |
Page 32 |
Page 33 |
Page 34 |
Page 35 |
Page 36 |
Page 37 |
Page 38 |
Page 39 |
Page 40 |
Page 41 |
Page 42 |
Page 43 |
Page 44 |
Page 45 |
Page 46 |
Page 47 |
Page 48 |
Page 49 |
Page 50 |
Page 51 |
Page 52 |
Page 53 |
Page 54 |
Page 55 |
Page 56 |
Page 57 |
Page 58 |
Page 59 |
Page 60 |
Page 61 |
Page 62 |
Page 63 |
Page 64 |
Page 65 |
Page 66 |
Page 67 |
Page 68 |
Page 69 |
Page 70 |
Page 71 |
Page 72 |
Page 73 |
Page 74 |
Page 75 |
Page 76 |
Page 77 |
Page 78 |
Page 79 |
Page 80 |
Page 81 |
Page 82 |
Page 83 |
Page 84 |
Page 85 |
Page 86 |
Page 87 |
Page 88 |
Page 89 |
Page 90 |
Page 91 |
Page 92